학술논문
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment †
Document Type
article
Author
Whelan, JS; Bielack, SS; Marina, N; Smeland, S; Jovic, G; Hook, JM; Krailo, M; Anninga, J; Butterfass-Bahloul, T; Böhling, T; Calaminus, G; Capra, M; Deffenbaugh, C; Dhooge, C; Eriksson, M; Flanagan, AM; Gelderblom, H; Goorin, A; Gorlick, R; Gosheger, G; Grimer, RJ; Hall, KS; Helmke, K; Hogendoorn, PCW; Jundt, G; Kager, L; Kuehne, T; Lau, CC; Letson, GD; Meyer, J; Meyers, PA; Morris, C; Mottl, H; Nadel, H; Nagarajan, R; Randall, RL; Schomberg, P; Schwarz, R; Teot, LA; Sydes, MR; Bernstein, M; Pickering, James; Joffe, Nicola; Kevric, Matthias; Sorg, Benjamin; Villaluna, Doojduen; Wang, Caroline; Perisoglou, Martha; Trani, Leonardo; Potratz, Jenny; Carrle, Dorothe; Wilhelm, Miriam; Zils, Katja; Teske, Carmen
Source
Annals of Oncology. 26(2)
Subject
Language
Abstract
BackgroundFour international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response.Patients and methodsPatients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery. Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with